Article
The pharmacogenetics of lithium response depends upon clinical co-morbidity.
Molecular diagnosis & therapy - 1 Jan 2007
Bremer Troy, Diamond Cornelius, McKinney Rebecca, Shehktman Tatyana, Barrett Thomas B, Herold Chris, Kelsoe John R
Abstract excerpt
BACKGROUND: Based on results from randomized, controlled clinical trials, lithium monotherapy or lithium with the addition of an antipsychotic remains a first-line treatment option for both acute and long-term mood stabilization in bipolar mania. However, response to lithium is poor in bipolar patients who exhibit clinical characteristics such as rapid cycling and mixed manic states, suggesting that they may have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.